NasdaqGM:MIRMBiotechs
Mirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?
In recent months, Mirum Pharmaceuticals reported very large year-over-year net product revenue growth, reached GAAP profitability, raised full-year revenue guidance to about US$500 million, and secured multiple new approvals and trial milestones for its rare disease portfolio, including LIVMARLI and CTEXLI.
This combination of improving financial performance and advancing late-stage studies, such as the EXPAND and VISTAS trials, is materially reshaping expectations for Mirum’s long-term rare...